Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2021 Apr 6;15(4):529-539.
doi: 10.1093/ecco-jcc/jjaa215.

Clinical Outcomes of Covid-19 in Patients With Inflammatory Bowel Disease: A Nationwide Cohort Study

Lauranne A A P Derikx  1 , Marten A Lantinga  1 , Dirk J de Jong  1 , Willemijn A van Dop  1 , Rob H Creemers  2 , Tessa E H Römkens  3 , Jeroen M Jansen  4 , Nofel Mahmmod  5 , Rachel L West  6 , Adriaan C I T L Tan  7 , Alexander G L Bodelier  8 , Moniek H P Gorter  9 , Paul J Boekema  10 , Eric R C Halet  11 , Carmen S Horjus  12 , Maarten A van Dijk  13 , Meike M C Hirdes  14 , Ludger S M Epping Stippel  15 , Bindia Jharap  16 , Maurice W M D Lutgens  17 , Maurice G Russel  18 , Lennard P L Gilissen  19 , Sjoukje Nauta  20 , Adriaan A van Bodegraven  2   21 , Frank Hoentjen  1
Affiliations
Multicenter Study

Clinical Outcomes of Covid-19 in Patients With Inflammatory Bowel Disease: A Nationwide Cohort Study

Lauranne A A P Derikx et al. J Crohns Colitis. .

Abstract

Background and aims: The COVID-19 risk and disease course in inflammatory bowel disease [IBD] patients remains uncertain. Therefore, we aimed to assess the clinical presentation, disease course, and outcomes of COVID-19 in IBD patients. Second, we determined COVID-19 incidences in IBD patients and compared this with the general population.

Methods: We conducted a multicentre, nationwide IBD cohort study in The Netherlands and identified patients with COVID-19. First, we assessed the COVID-19 disease course and outcomes. Second, we compared COVID-19 incidences between our IBD study cohort and the general Dutch population.

Results: We established an IBD cohort of 34 763 patients. COVID-19 was diagnosed in 100/34 763 patients [0.29%]; 20/100 of these patients [20%] had severe COVID-19 defined as admission to the intensive care unit, mechanical ventilation, and/or death. Hospitalisation occurred in 59/100 [59.0%] patients and 13/100 [13.0%] died. All patients who died had comorbidities and all but one were ≥65 years old. In line, we identified ≥1 comorbidity as an independent risk factor for hospitalisation (odds ratio [OR] 4.20, 95% confidence interval [CI] 1.58-11.17,; p = 0.004). Incidences of COVID-19 between the IBD study cohort and the general population were comparable (287.6 [95% CI 236.6-349.7] versus 333.0 [95% CI 329.3-336.7] per 100000 patients, respectively; p = 0.15).

Conclusions: Of 100 cases with IBD and COVID-19, 20% developed severe COVID-19, 59% were hospitalised and 13% died. A comparable COVID-19 risk was found between the IBD cohort [100/34 763 = 0.29%] and the general Dutch population. The presence of ≥1 comorbidities was an independent risk factor for hospitalisation due to COVID-19.

Keywords: Crohn’s disease; Ulcerative colitis; intensive care unit; mortality; severe COVID-19.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Forest plot comparing the reported COVID-19 incidence during 4 months between the IBD Study cohort and general Dutch population. NC, not computable.
Figure 2.
Figure 2.
Reported COVID-19 incidence per 100 000 patients per 2 weeks for both the IBD Study cohort and the general Dutch population in the corresponding region.
Figure 3.
Figure 3.
Forest plot comparing the hospitalised COVID-19 incidence during 4 months between the IBD Study cohort and general Dutch population. NC, not computable.
Figure 4.
Figure 4.
Hospitalised COVID-19 incidence per 100 000 patients per 2 weeks for both the IBD Study cohort and the general Dutch population in the corresponding region.
Figure 5.
Figure 5.
COVID-19 mortality per 100 000 patients per 2 weeks for both the IBD Study cohort and the general Dutch population in the corresponding region.
See this image and copyright information in PMC

References

    1. Monteleone G, Ardizzone S. Are patients with inflammatory bowel disease at increased risk for Covid-19 infection? J Crohns Colitis 2020;14:1334–6. - PMC - PubMed
    1. Guan Wj, Ni Zy, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708–20. doi: 10.1056/NEJMoa2002032. - DOI - PMC - PubMed
    1. Rubin DT, Abreu MT, Rai V, Siegel CA; International Organization for the Study of Inflammatory Bowel Disease . Management of patients with Crohn’s disease and ulcerative colitis during the coronavirus disease-2019 pandemic: results of an International Meeting. Gastroenterology 2020;159:6–13.e6. - PMC - PubMed
    1. Rahier JF, Magro F, Abreu C, et al. ; European Crohn’s and Colitis Organisation [ECCO]. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2014;8:443–68. - PubMed
    1. Neurath MF. Covid-19 and immunomodulation in IBD. Gut 2020. doi:gutjnl-2020–321269. - PMC - PubMed

Publication types

MeSH terms